Yet another writer accuses Jose Bautista of PED use

29 Comments

Bob Frantz of the San Francisco Examiner wrote an odious little column today in which he accused Jose Bautista of using performance enhancing drugs.

Well, he didn’t directly accuse him of doing so. No, he’s far too savvy for that.  He merely wrote that “questions remain” regarding Bautista. Said that “normal men don’t go from 13 home runs as a part-time utility player one year to 52 home runs.” He merely suggested that Bautista submit to urine and blood tests and then have the results released to the public. He then blamed his suspicion and subtle character assassination on Jose Canseco, Rafael Palmiero, Roger Clemens and other people who presumably do not have editorial control over Frantz’s columns at the Examiner.

Of course, the fact that he blames Canseco et al, for his own cynical and evidence-free
suspicions of Bautista is intellectual dishonesty at its finest. He clearly suspects
Bautista of using PEDs. If he didn’t, he wouldn’t have been
inspired to write this piece. Well, he wouldn’t have unless the piece itself is a cynical exercise in filling column inches and stirring the pot by peddling crap that the author does not himself believe, but let’s save that for another time.

For now let us merely note that if Frantz has the guts to make an actual accusation, he should make it. To state, in plain language, that he doubts that Bautista’s accomplishments are genuine. To do otherwise — to make oblique reference to
the mere possibility that Bautista cheated and to blame
figures who haven’t played baseball for several years for “the questions
that remain” — is cowardly.
 
And that goes not only for Frantz, but for anyone who wishes to join in the increasingly popular pastime of trashing Jose Bautista. Ladies and gentlemen: if you have evidence, or even reasonable suspicion that Bautista — a
player who has had at least two PED tests this season — has used PEDs,
come out and say it.  If you don’t, please spare us your insinuations to
the contrary.

Danny Espinosa reportedly skipped Nationals Winterfest because of Adam Eaton

WASHINGTON, DC - OCTOBER 13: Danny Espinosa #8 of the Washington Nationals celebrates after teammate Chris Heisey #14 (not pictured) hits a two run home run in the seventh inning against the Los Angeles Dodgers during game five of the National League Division Series at Nationals Park on October 13, 2016 in Washington, DC. (Photo by Rob Carr/Getty Images)
Getty Images
8 Comments

According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.

A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.

Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.

Espinosa will reach free agency after the 2017 season.

Nick Cafardo: Red Sox should deal Pomeranz, not Buchholz

BOSTON, MA - SEPTEMBER 18: Drew Pomeranz #31 of the Boston Red Sox pitches during the first inning against the New York Yankees at Fenway Park on September 18, 2016 in Boston, Massachusetts. The Red Sox won 5-4. (Photo by Rich Gagnon/Getty Images)
Getty Images
11 Comments

The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.

The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.

Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.

Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.